Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immunex Enbrel panel on Tuesday

The FDA's Arthritis Drugs Advisory Committee will consider on Tuesday IMNX's application to expand the indications for the company's Enbrel TNF inhibitor to include patients with early rheumatoid

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE